JP2012520081A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012520081A5 JP2012520081A5 JP2011554211A JP2011554211A JP2012520081A5 JP 2012520081 A5 JP2012520081 A5 JP 2012520081A5 JP 2011554211 A JP2011554211 A JP 2011554211A JP 2011554211 A JP2011554211 A JP 2011554211A JP 2012520081 A5 JP2012520081 A5 JP 2012520081A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- polypeptide
- seq
- angiogenesis
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 229920001184 polypeptide Polymers 0.000 claims 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims 31
- 150000001413 amino acids Chemical class 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 230000033115 angiogenesis Effects 0.000 claims 8
- 230000002491 angiogenic effect Effects 0.000 claims 6
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 5
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 206010058558 Hypoperfusion Diseases 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 230000006862 enzymatic digestion Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000006274 Brain Stem Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 239000012623 DNA damaging agent Substances 0.000 claims 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010061968 Gastric neoplasm Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010029098 Neoplasm skin Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000009104 chemotherapy regimen Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000023963 corpus uteri neoplasm Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 201000011523 endocrine gland cancer Diseases 0.000 claims 1
- 239000004052 folic acid antagonist Substances 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000004959 laryngeal benign neoplasm Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000002197 limbic effect Effects 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000025402 neoplasm of esophagus Diseases 0.000 claims 1
- 208000025189 neoplasm of testis Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 208000025303 orbit neoplasm Diseases 0.000 claims 1
- 201000000890 orbital cancer Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000011252 penile benign neoplasm Diseases 0.000 claims 1
- 208000023974 pharynx neoplasm Diseases 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 230000000861 pro-apoptotic effect Effects 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 208000013718 rectal benign neoplasm Diseases 0.000 claims 1
- 201000008946 renal pelvis neoplasm Diseases 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 208000014680 small intestine neoplasm Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 208000013076 thyroid tumor Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 208000026517 ureter neoplasm Diseases 0.000 claims 1
- 201000011476 ureteral benign neoplasm Diseases 0.000 claims 1
- 208000029584 urinary system neoplasm Diseases 0.000 claims 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15932209P | 2009-03-11 | 2009-03-11 | |
| US61/159,322 | 2009-03-11 | ||
| PCT/US2010/027041 WO2010105097A2 (en) | 2009-03-11 | 2010-03-11 | Sparc angiogenic domain and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012520081A JP2012520081A (ja) | 2012-09-06 |
| JP2012520081A5 true JP2012520081A5 (https=) | 2013-05-02 |
Family
ID=42729116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011554211A Pending JP2012520081A (ja) | 2009-03-11 | 2010-03-11 | Ｓｐａｒｃ血管新生ドメイン及び使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20120087910A1 (https=) |
| EP (1) | EP2405932A4 (https=) |
| JP (1) | JP2012520081A (https=) |
| KR (2) | KR20130043242A (https=) |
| CN (2) | CN103724417A (https=) |
| AU (1) | AU2010224031B2 (https=) |
| BR (1) | BRPI1009457A2 (https=) |
| CA (1) | CA2755109A1 (https=) |
| IL (2) | IL215089A0 (https=) |
| MX (1) | MX2011009478A (https=) |
| NZ (1) | NZ595528A (https=) |
| WO (1) | WO2010105097A2 (https=) |
| ZA (1) | ZA201107415B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013522235A (ja) * | 2010-03-11 | 2013-06-13 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Ｓｐａｒｃ血管新生領域及びその使用法 |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| CN120361186B (zh) * | 2025-04-15 | 2025-12-30 | 北京大学口腔医学院 | 一种促进血管生成和组织再生的药物组合物及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002000677A1 (en) * | 2000-06-07 | 2002-01-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| AU2006237613A1 (en) * | 2005-02-18 | 2006-10-26 | Abraxis Bioscience, Inc. | Q3 SPARC deletion mutant and uses thereof |
| US8440625B2 (en) * | 2006-06-26 | 2013-05-14 | University Of British Columbia | Secreted protein acidic and rich in cysteine (SPARC) as chemotherapeutic sensitizers |
| ES2389828T3 (es) * | 2007-04-13 | 2012-11-02 | Abraxis Bioscience, Inc. | Composiciones que comprenden polipéptidos SPARC |
-
2010
- 2010-03-11 WO PCT/US2010/027041 patent/WO2010105097A2/en not_active Ceased
- 2010-03-11 MX MX2011009478A patent/MX2011009478A/es not_active Application Discontinuation
- 2010-03-11 US US13/256,135 patent/US20120087910A1/en not_active Abandoned
- 2010-03-11 BR BRPI1009457A patent/BRPI1009457A2/pt not_active IP Right Cessation
- 2010-03-11 KR KR1020137008481A patent/KR20130043242A/ko not_active Ceased
- 2010-03-11 EP EP10751447A patent/EP2405932A4/en not_active Withdrawn
- 2010-03-11 JP JP2011554211A patent/JP2012520081A/ja active Pending
- 2010-03-11 KR KR1020117023819A patent/KR20110139256A/ko not_active Ceased
- 2010-03-11 CN CN201410016511.2A patent/CN103724417A/zh active Pending
- 2010-03-11 CN CN201080018313XA patent/CN102482334A/zh active Pending
- 2010-03-11 NZ NZ595528A patent/NZ595528A/xx not_active IP Right Cessation
- 2010-03-11 CA CA2755109A patent/CA2755109A1/en not_active Abandoned
- 2010-03-11 AU AU2010224031A patent/AU2010224031B2/en not_active Ceased
-
2011
- 2011-09-11 IL IL215089A patent/IL215089A0/en unknown
- 2011-10-10 ZA ZA2011/07415A patent/ZA201107415B/en unknown
-
2013
- 2013-10-08 IL IL228795A patent/IL228795A0/en unknown
- 2013-11-12 US US14/078,119 patent/US20140094416A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012520081A5 (https=) | ||
| Wood et al. | Molecular histology of lung cancer: from targets to treatments | |
| JP2012521768A5 (https=) | ||
| Zhang et al. | Silencing of LncRNA HULC enhances chemotherapy induced apoptosis in human gastric cancer | |
| Friedländer et al. | ErbB-directed immunotherapy: antibodies in current practice and promising new agents | |
| HRP20231525T1 (hr) | Postupci i pripravci za dijagnozu i liječenje raka | |
| US20200360296A1 (en) | Nanoparticle-hydrogel composite for nucleic acid molecule delivery | |
| AU2017224226A1 (en) | Compositions and methods of using piRNAs in cancer diagnostics and therapeutics | |
| Kutova et al. | The multifaceted role of connexins in tumor microenvironment initiation and maintenance | |
| JP2009523739A5 (https=) | ||
| Miura et al. | Splice variants in apoptotic pathway | |
| RU2016140214A (ru) | Адресное воздействие на устойчивый к трастузумабу her2+ рак молочной железы посредством her3-нацеленных наночастиц | |
| JP2012529293A5 (https=) | ||
| Tang et al. | Novel insights into the multifaceted roles of m6A-modified LncRNAs in cancers: biological functions and therapeutic applications | |
| JP2016127833A (ja) | 癌治療のための薬剤標的としてのＦｒａ−１標的遺伝子 | |
| JP2005520543A5 (https=) | ||
| Wang et al. | Pathological and therapeutic aspects of long noncoding RNAs in osteosarcoma | |
| ES2398391T3 (es) | Polinucleótidos relacionados con cáncer de colon | |
| US20200009177A1 (en) | Methods of inhibiting cancer stem cells with hmga1 inhibitors | |
| JP2009523004A5 (https=) | ||
| CN105859841B (zh) | 一种双靶向嵌合肽及其在制备抗肿瘤转移药物中的应用 | |
| EP3004153A1 (en) | Recombinant cancer therapeutic cytokine | |
| De Silva et al. | The Elusive Road Towards Effective Cancer Prevention and Treatment | |
| Kosmidis et al. | Gene therapy for hepatocellular carcinoma: An update | |
| JP2015174843A5 (https=) |